{
    "clinical_study": {
        "@rank": "105931", 
        "arm_group": [
            {
                "arm_group_label": "Pulmonary fibrosis patients", 
                "description": "Patients with pulmonary fibrosis of any cause (idiopathic, connective tissue disease, chronic hypersensitivity pneumonitis)"
            }, 
            {
                "arm_group_label": "Primary supporter/caregiver of patient with pulmonary fibrosis", 
                "description": "We will interview primary supporters/caregivers of people living with PF to learn from a different perspective of what it's like to use supplemental oxygen, both for the person living with PF and the primary supporter him/herself."
            }, 
            {
                "arm_group_label": "Prescribers of supplemental oxygen", 
                "description": "We will interview supplemental oxygen prescribers to better understand their practices around prescribing oxygen and their expectations for the patients to  whom they prescribe supplemental oxygen."
            }
        ], 
        "brief_summary": {
            "textblock": "To enhance understanding of supplemental oxygen\u2014its utility in and adoption by patients with\n      pulmonary fibrosis\u2014by examining how patients perceive it and by determining how perceptions\n      and patient-centered outcome measures change from before to after supplemental oxygen is\n      prescribed."
        }, 
        "brief_title": "Supplemental Oxygen in Pulmonary Fibrosis", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Fibrosis", 
                "Pulmonary Fibrosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The investigators aim to recruit patients with PF to participate in interviews and/or a\n      one-year study of supplemental oxygen (O2).  In the one-year study, the investigators will\n      collect data before and for one year after PF patients are prescribed daily-use supplemental\n      oxygen and compare outcomes, including shortness of breath, quality of life, fatigue, cough,\n      and day-to-day functioning before and after O2.\n\n      In addition to this, the investigators will interview O2 prescribers and primary\n      supporters/caregivers of PF patients prescribed daily-use O2 to understand the perceptions\n      of others affected by supplemental O2."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patient-Participants\n\n        (Using daily 02 therapy at time of enrollment)\n\n          -  Diagnosis of PF\n\n          -  Able to read and speak English\n\n          -  Has been on daily-use supplemental oxygen for more than one year\n\n        (Not using daily 02 therapy at time of enrollment)\n\n          -  Diagnosis of PF\n\n          -  Able to read, speak and write in English\n\n          -  Has not been prescribed daily-use supplemental oxygen\n\n          -  Forced vital capacity <75% and diffusing capacity <65% of predicted values\n\n          -  Subject's physician allows the subject to abstain from daily-use supplemental oxygen\n             for 7-10 days after prescription to allow data for collection\n\n        Primary Supporters\n\n          -  Self-report status of providing care or support to a person living with pulmonary\n             fibrosis who has used supplemental oxygen for more than one year\n\n          -  Able to speak English\n\n        O2 Prescribers\n\n          -  Self-report status of being a prescriber of daily-use supplemental oxygen to PF\n             patients\n\n          -  Able to speak English"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with pulmonary fibrosis of any cause (idiopathic, related to connective tissue\n        disease [e.g., rheumatoid arthritis, systemic sclerosis/scleroderma,\n        dermato-/polymyositis, sjogren's syndrome], familial or genetic) or the primary\n        supporter/caregiver of a patient with pulmonary fibrosis"
            }
        }, 
        "enrollment": {
            "#text": "360", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01961362", 
            "org_study_id": "PCORI 4134a"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pulmonary fibrosis", 
            "Interstitial lung disease", 
            "Connective tissue disease", 
            "Chronic hypersensitivity pneumonitis", 
            "Idiopathic pulmonary fibrosis", 
            "Pulmonary fibrosis of any cause", 
            "Primary supporters/caregivers"
        ], 
        "lastchanged_date": "October 10, 2013", 
        "link": {
            "description": "This is a link to the Current Studies page of pulmonaryfibrosisresearch.org.  It contains information about the study and how to contact study personnel.", 
            "url": "http://pulmonaryfibrosisresearch.org/current-studies"
        }, 
        "location": {
            "contact": {
                "last_name": "Amanda Belkin, MPH"
            }, 
            "facility": {
                "address": {
                    "city": "Denver", 
                    "country": "United States", 
                    "state": "Colorado", 
                    "zip": "80206"
                }, 
                "name": "National Jewish Health Interstitial Lung Disease Program"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "3", 
        "official_title": "Observing the Effects of Supplemental Oxygen on Patients With Pulmonary Fibrosis", 
        "overall_contact": {
            "email": "support@PFresearch.org", 
            "last_name": "Amanda Belkin, MPH", 
            "phone": "855-609-0010"
        }, 
        "overall_official": {
            "affiliation": "National Jewish Health", 
            "last_name": "Jeff Swigris, DO, MS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in dyspnea from immediately prior to one month after starting daily-use supplemental oxygen", 
            "safety_issue": "No", 
            "time_frame": "One month post daily-use supplemental oxygen implementation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01961362"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in quality of life, fatigue and cough from prior to one month after daily-use supplemental oxygen implementation", 
                "safety_issue": "No", 
                "time_frame": "One month after daily-use supplemental oxygen implementation"
            }, 
            {
                "description": "Functioning will be captured by having patients wear an activity monitor, and activity space will be capture by having patients wear a mobile GPS recorder.", 
                "measure": "Change in day-to-day functioning and activity space from prior to one month after daily-use supplemental oxygen implementation", 
                "safety_issue": "No", 
                "time_frame": "One month after daily-use supplemental oxygen implementation"
            }
        ], 
        "source": "National Jewish Health", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "The Coalition for Pulmonary Fibrosis", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Pulmonary Fibrosis Foundation", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "National Jewish Health", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}